The impact of combining the CML-BC with Evi1 upregulation is in strong contrast to that of the simple BCR–ABL BMT model, which only leads to CML-CP in mice 3–4 weeks after inoculation (Figure 4h). The gene discussed is MECOM; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.